Barclays’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-66
| Closed | – | – | 7604 |
|
|
2019
Q1 | $0 | Hold |
66
| – | – | ﹤0.01% | 7671 |
|
|
2018
Q4 | $0 | Hold |
66
| – | – | ﹤0.01% | 7814 |
|
|
2018
Q3 | $0 | Hold |
66
| – | – | ﹤0.01% | 7717 |
|
|
2018
Q2 | $0 | Sell |
66
-46
| -41% | -$134 | ﹤0.01% | 7649 |
|
|
2018
Q1 | $0 | Sell |
112
-29,548
| -100% | -$81.4K | ﹤0.01% | 7659 |
|
|
2017
Q4 | $121K | Buy |
29,660
+27,792
| +1,488% | +$121K | ﹤0.01% | 5097 |
|
|
2017
Q3 | $8K | Sell |
1,868
-64,793
| -97% | -$262K | ﹤0.01% | 6263 |
|
|
2017
Q2 | $222K | Buy |
66,661
+19,762
| +42% | +$82K | ﹤0.01% | 4285 |
|
|
2017
Q1 | $432K | Buy |
46,899
+6,921
| +17% | +$60.8K | ﹤0.01% | 3543 |
|
|
2016
Q4 | $308K | Sell |
39,978
-44,617
| -53% | -$410K | ﹤0.01% | 3817 |
|
|
2016
Q3 | $966K | Sell |
84,595
-17,338
| -17% | -$202K | ﹤0.01% | 2657 |
|
|
2016
Q2 | $1.25M | Sell |
101,933
-15,604
| -13% | -$189K | ﹤0.01% | 2409 |
|
|
2016
Q1 | $1.18M | Buy |
117,537
+105,972
| +916% | +$1.24M | ﹤0.01% | 2399 |
|
|
2015
Q4 | $254K | Buy |
11,565
+2,456
| +27% | +$50.3K | ﹤0.01% | 3720 |
|
|
2015
Q3 | $146K | Buy |
9,109
+8,703
| +2,144% | +$174K | ﹤0.01% | 4366 |
|
|
2015
Q2 | $9K | Sell |
406
-1,504
| -79% | -$37.1K | ﹤0.01% | 6176 |
|
|
2015
Q1 | $48K | Buy |
1,910
+480
| +34% | +$12.2K | ﹤0.01% | 5320 |
|
|
2014
Q4 | $30K | Sell |
1,430
-1,494
| -51% | -$30.6K | ﹤0.01% | 6080 |
|
|
2014
Q3 | $52K | Sell |
2,924
-4,225
| -59% | -$84.9K | ﹤0.01% | 5861 |
|
|
2014
Q2 | $165K | Buy |
7,149
+2,008
| +39% | +$49.6K | ﹤0.01% | 4999 |
|
|
2014
Q1 | $169K | Buy |
5,141
+4,996
| +3,446% | +$168K | ﹤0.01% | 4947 |
|
|
2013
Q4 | $4K | Sell |
145
-120
| -45% | -$2.2K | ﹤0.01% | 7255 |
|
|
2013
Q3 | $4K | Buy |
+265
| New | +$4.91K | ﹤0.01% | 7089 |
|
Barclays's OMED Position: Q2 2019 in Review
Barclays sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 66 shares.
Barclays first reported a position in OMED in Q3 2013 and held it in 23 quarters. The position peaked at $1.25M in Q2 2016. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Barclays reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Barclays sold 66 OncoMed Pharmaceuticals, Inc. shares in Q2 2019.
- Barclays first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 23 quarters.
- Barclays's OncoMed Pharmaceuticals, Inc. position peaked at $1.25M in Q2 2016.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Barclays's 13F filing for Q2 2019, filed 14 Aug 2019.